PF-Atlas › Clinical Trials › NCT07363304

Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.

Elexacaftor, Tezacaftor, Ivacaftor · Not specified

Registry ID
NCT07363304
Phase
Not specified
Status
Recruiting
Drug / intervention
Elexacaftor, Tezacaftor, Ivacaftor
Sponsor
Meyer Children's Hospital IRCCS
Start
2025-12-02

About this trial

Elexacaftor, Tezacaftor, Ivacaftor is evaluated in NCT07363304, a idiopathic pulmonary fibrosis study sponsored by Meyer Children's Hospital IRCCS. Current status: Recruiting.

View NCT07363304 on ClinicalTrials.gov →

Explore related

All Elexacaftor, Tezacaftor, Ivacaftor trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT07363304 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.